Intracerebral hemorrhage (ICH) is a subtype of stroke that is followed by primary and secondary brain injury. As a result of the injury, cell metabolism is disrupted and a series of stress responses are activated, such as endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), leading to the re-establishment of cell homeostasis or cell death. As an important mechanism of cell homeostasis, autophagy has been widely studied, and the associations between autophagy, ER stress, and the UPR have also been demonstrated. Whether these mechanisms are beneficial or detrimental remains a matter of controversy, but there is no doubt as to their vital functions. An understanding of the mechanisms of injury and recovery after ICH is crucial to develop therapeutic strategies. In this review, we summarize the related studies and highlight the roles of autophagy, ER stress, and the UPR in disease, especially in ICH. We also provide an overview of therapeutic approaches that target autophagy, and we discuss the prospects for modulating autophagy, ER stress, and UPR mechanisms in ICH therapy.

**Keywords**
- Intracerebral hemorrhage
- unfolded protein response
- ER stress
- autophagy
- therapy

**Abstract**
Intracerebral hemorrhage (ICH) is a subtype of stroke that is followed by primary and secondary brain injury. As a result of the injury, cell metabolism is disrupted and a series of stress responses are activated, such as endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), leading to the re-establishment of cell homeostasis or cell death. As an important mechanism of cell homeostasis, autophagy has been widely studied, and the associations between autophagy, ER stress, and the UPR have also been demonstrated. Whether these mechanisms are beneficial or detrimental remains a matter of controversy, but there is no doubt as to their vital functions. An understanding of the mechanisms of injury and recovery after ICH is crucial to develop therapeutic strategies. In this review, we summarize the related studies and highlight the roles of autophagy, ER stress, and the UPR in disease, especially in ICH. We also provide an overview of therapeutic approaches that target autophagy, and we discuss the prospects for modulating autophagy, ER stress, and UPR mechanisms in ICH therapy.

**Introduction**
Autophagy plays an important role in cell metabolism and disease pathology [1-3]. This intracellular mechanism is essential for cell survival, facilitating the breakdown and eventual recycling of macromolecules during cellular adaptation to environmental changes. The endoplasmic reticulum (ER) is an organelle wherein proteins are synthesized, matured, and secreted. When a cell experiences stress conditions, such as starvation, redox imbalance, altered protein glycosylation, or protein folding defects, the normal functioning of the ER in protein synthesis is disrupted, and the ER switches to a stress state. As misfolded proteins accumulate, the unfolded protein response (UPR) is initiated to counter these stress effects [4,5]. The eventual outcome of ER stress determines whether a cell survives or undergoes programmed cell death [6]. The significant role of the ER stress-associated UPR in disease has been well studied [7-9]. It has been widely reported that autophagy is associated with several neurologic diseases, such as Alzheimer’s disease (AD) [10,11], Parkinson’s disease (PD) [12], amyotrophic lateral sclerosis (ALS) [2], subarachnoid hemorrhage and ICH [13,14]. As a subtype of stroke, intracerebral hemorrhage (ICH) is often associated with high mortality and morbidity [15], as well as with poor clinical outcomes. 20% of patients are functionally independent at 6 months after experiencing ICH [16], and survivors often suffer from serious neurologic impairments [17]. With the growing understanding of brain injury mechanisms after ICH, preventing brain injury and promoting neuronal survival have emerged as therapeutic goals. In this review, we provide an overview of the associations between autophagy, ER stress, and the UPR, as well as their roles in disease pathology, especially in ICH, and we highlight potential treatment strategies.

**The mechanism of autophagy**
In mammalian cells, there are three predominant subtypes of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). The term macroautophagy refers primarily to common autophagy. During macroautophagy, a double-membrane sequestering compartment is formed as phagophore and matures into an autophagosome. Following delivery to the vacuole or lysosome, the cargo is degraded and the resulting macromolecules are released back into the cytosol for reuse [18]. In microautophagy, the membrane of the lysosome invaginates and differentiates into an autophagic tube to enclose or engulf the cytosol directly. However, misfolded or unfolded proteins and other cytoplasmic material can also be imported by CMA directly into lysosomes, where they continue to be digested with the help of HSPA8/HSC70 (heat shock 70-kDa protein 8) [19]. Protein substrates containing a “KFERQ”-like motif are recognized by the constitutive heat shock cognate 70 (HSC70) chaperone and delivered to the lysosomes upon binding to lysosome-associated membrane protein (LAMP)2A receptors on the lysosomal membrane [20]. Another subtype of autophagy is noncanonical
autophagy [21], in which phagocytes kill or digest extracellular pathogens directly.

The activation of autophagy can be detected by transmission electron microscopy (TEM) during the development of phagophores (isolation membranes) and autophagosomes. The morphologic process of autophagy is shown in Figure 1. Based on our current knowledge, it appears that the formation of autophagosomes is regulated by a suite of proteins encoded by autophagy-related genes (ATGs). These genes, which are highly evolutionarily conserved, were originally discovered in yeast and have been systematically studied [22]. The initiation of autophagy could be induced by the dissociation of Beclin 1 (the mammalian ortholog of yeast autophagy-related gene 6, ATG6) from its inhibitors [23]. The extension of the isolation membrane is regulated by an ubiquitin-like conjugating system that converts LC3 (microtubule-associated protein 1 light chain 3, the mammalian homolog of yeast ATG8 ) from its free (LC3-I) to its lipidated, membrane bound (LC3-II) form [24]. The ULK1 (Serine/Threonine-Protein Kinase, also known as Unc-51 Like Autophagy Activating Kinase 1) complex [25] is also required during membrane initiation. The activation of the ULK complex is regulated by mTORC1 (mammalian target of rapamycin complex 1) and AMPK (AMP-activated protein kinase). The mTORC1 kinase complex consists of five subunits [26]: mTOR (mammalian target of rapamycin), RAPTOR (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with SEC13 protein), DEPTOR (DEP domain–containing mTOR-interacting protein), and PRAS40 (40-kDa Pro-rich AKT substrate). mTOR is a central cell-growth regulator that integrates growth factors and nutrient signals. AMPK is a key energy sensor and regulates cellular metabolism to maintain energy homeostasis. Under nutrient sufficiency conditions, high mTOR activity prevents ULK1 activation by phosphorylating ULK1 Ser757 and disrupting ULK1 and AMPK interaction [27]. Conversely, under starvation or toxin accumulation, down-regulated mTORC1 leads to the activation of the ULK complex, resulting in the induction of autophagy [28]. AMPK also promotes autophagy by the direct activation of ULK1 through phosphorylation of Ser317 and Ser777 under glucose starvation [27]. During the process of autophagy induction, a mammalian-specific scaffold protein named AMBRA1 (activating Molecule in Beclin-1-Regulated Autophagy) is phosphorylated by ULK1 and translocates to the ER, where it can prime autophagosome formation [29]. These activations are also associated with the Beclin 1 complex (the autophagy-specific class III phosphoinositide-3-kinase complex, CII P3K) [30] and the ULK complex [31].

Some ULK complex and P3K (phosphoinositide-3-kinase) complex phosphorylated proteins usually contribute to the closure of the isolation membrane and the nucleation of the autophagosome; examples of these proteins are PtdIns (3) (phosphorylatedinositol-3-phosphate) [32] and Jumpy (a myotubularin-related phosphoinositide-3-phosphate phosphatase, also known as MTMR14) [33]. During the maturation of an autophagosome, LC3-II binds to the membrane and aids the expansion, making LC3 family protein a useful marker for identifying autophagosomes [34]. In contrast, the ATG proteins dissociate from the membrane before maturation, with the exception of ATG9, which participates in vesicles and lipid delivery and is involved in the entire process [35,36]. In response to starvation, phosphorylation of mATG9 by ULK1 promotes the interactions between mATG9 and the adaptor protein complex, leading to redistribution of mATG9 from the plasma membrane and juxta-nuclear region to the peripheral pool for autophagy initiation [36]. The origin and mechanism of autophagosome formation are not fully understood; however, the origin of the isolation membrane is considered to be associated with several cellular organelles, especially the ER, mitochondria, and Golgi apparatus [37].

Pathways associated with ER stress and the UPR

The hypothesis that misfolded or unfolded proteins and the UPR might be the primary promoters of cells surviving ER stress was first proposed in the 1980s [38] and led to
the investigation of the influence of ER stress and the UPR on cell survival [39,40]. The UPR consists of three main signaling systems that are initiated by prototypical ER-localized stress sensors: PERK (protein kinase RNA–like endoplasmic reticulum kinase), IRE1 (inositol-requiring enzyme 1), and ATF6 (activating transcription factor 6). These three sensors are all associated with Grp78 (glucose-regulated protein 78 kDa, a key ER chaperone that is also known as BiP), which controls their activation through a binding/release mechanism. Ordinarily, the activation of PERK, IRE1, and ATF6 is prevented by the binding of Grp78. However, when a cell is experiencing stress conditions, with misfolded or unfolded proteins accumulating in its ER, Grp78 switches its binding site to the hydrophobic domains and releases the sensors [41], thereby promoting the oligomerization and transphorylation of IRE1 and PERK [42] and revealing an ER export motif in ATF6 [43](as shown in Figure 2).

The PERK pathway
Under stress conditions, the protein kinase domain on PERK is activated, promoting its oligomerization and trans-auto-phosphorylation [44]. Phosphorylation of the α-subunit of EIF2 (eukaryotic initiation factor 2) subsequently inhibits EIF2β (a guanine nucleotide exchange factor), resulting in translation attenuation and reducing the excess of newly synthesized protein. Alternatively, phosphorylated EIF2 increases the translation of ATF4 (activating transcription factor 4) and induces the expression of ER-stress target genes to support the recovery of translation. A study in murine cells [45] found that the PERK-EIF2α signaling pathway was also involved in polyQ72-induced ATG12 upregulation and LC3 conversion, suggesting the pro-survival role that PERK-EIF2α pathway plays in autophagy. Another study [46] revealed that, in addition to reducing the protein overload in the ER, the inhibition of translation by PERK-EIF2α phosphorylation also increased the levels of p53 (transformation-related protein 53) through a PERK-dependent ribosomal-Hdm2 (human homolog of mouse double minute 2, also known as E3 ubiquitin-protein ligase MDM2) interaction, leading to cell cycle inhibition. Interestingly, the PERK-EIF2α pathway can also increase the expression of a protein phosphatase gene named GADD34 (DNA damage-inducible gene 34) and dephosphorylate EIF2 to restore global protein synthesis, which might be a feedback mechanism to maintain translation coordination [47].

The IRE1 pathway
As an ER-resident transmembrane kinase/RNase, IRE1 monitors the status of protein folding inside the ER in a similar manner to the PERK/EIF2α pathway. Grp78 dissociation initiates IRE1 dimerization and phosphorylation, inducing the splicing of XBP1 (X-box binding protein 1) mRNA and activating the expression of UPR target genes.
mRNA [48], which is also activated by cytosolic kinase/endoribonuclease (RNase) domains [49]. Spliced XBP1 (sXBP1) mRNA is translated to a transcription factor that up-regulates the target genes via the ERSE (ER stress response element) promoter. sXBP1 is also involved in several aspects of ER function and physiology, such as protein folding, quality control, and the ERAD (ER-associated degeneration) system [50]. RNase substrate activation of IRE1α is restricted by its oligomerization status. Under conditions of chronic ER stress, the over-oligomerized IRE1α expands its substrates to include many ER-localized mRNAs, resulting in RIDD (regulated IRE1-dependent decay of mRNA) or apoptosis, whereas lower levels of oligomerization will block RIDD and maintain XBP1 splicing [48] to reduce cell degeneration.

The ATF6 pathway
As one of the stress response related transmembrane transcription factors, ATF6 has two isoforms in mammalian cells, ATF6α and ATF6β [51]. ATF6α and ATF6β are cleaved during the ER stress response. The resulting N-ATF6α and N-ATF6β have conserved DNA-binding domains and divergent transcriptional activation domains. N-ATF6β potentially acts as an endogenous transcriptional repressor of N-ATF6α. N-ATF6α and N-ATF6β translocate to the nucleus, bind to specific regulatory elements, and influence expression of ER stress response genes (e.g. GRP78) that contribute to resolving the ER stress response. Accordingly, cell viability are enhanced [52]. When a cell is under stress, ATF6 undergoes trans-Golgi migration instead of binding to the ER as usual, and an N-terminal DNA-binding transcription factor domain is released, catalyzed by two Golgi-resident enzymes named S1P and S2P proteases [44]. In addition to Grp78 dissociation, which is similar to that which occurs in PERK and IRE1 activation, the redox state of ATF6 is also involved in ER stress sensing and ATF6 activation [53]. Subsequently, the ATF6α cytosolic domain translocates to the nucleus and promotes adaptation processes, e.g., by activating the transcription of UPR target genes and AKT (also known as protein kinase B or PKB), resulting in negative regulation of mTORC1 and ULK1 activities [54]. A study conducted in ATF6α and ATF6β knockout mice showed that the maintenance of ER chaperones in mammalian cells depends on the function of ATF6, rather than that of IRE1 (as in worm and fly cells) [55]. However, the regulation of the ATF6 signal is highly dynamic and initially depends on the experimental system used, especially on the intensity of the stress induced by the different pharmacologic stressors [56]. Several regulators have been suggested to be involved in mediating ATF6, including WFS1 (Wolfram syndrome 1) [57] and PDIA5 (protein disulfide isomerase A5) [58], which have been implicated, respectively, in the degradation and activation of ATF6.

The activation of PERK, IRE1, and ATF6 produces several cytoprotective effects, such as reduced translation, enhanced ER protein-folding capacity, and clearance of misfolded ER proteins. UPR stress sensors are associated with many transcription factors and mediate the establishment of transcriptional patterns, indicating the functional role of the UPR in proteostasis.

Crosstalk between autophagy, ER stress, and the UPR
The associations between autophagy, ER stress, and the UPR have been demonstrated by several studies. As an essential organelle in which protein is processed and synthesized, the ER monitors protein folding, unpredicted errors and off-pathway intermediations during protein quality control. Under severe conditions, an overload of toxic polypeptides can challenge the capacity of the chaperone system, resulting in ER stress. The activation of the UPR promotes the refolding of non-native polypeptides or their elimination via ERAD and ER stress-activated autophagy [59]. It was initially thought that ER stress initiates autophagy only when aggregated proteins become excessive enough to overwhelm the canonical ubiquitin-proteasome-dependent ERAD. However, current findings suggest that ERAD-mediated proteins that are partially processed are also targets of autophagy. These encompass all other unfolded proteins [60]. ER stress-induced deactivation of mTOR contributes to the downregulation of AKT/
Autophagy in ICH and other diseases

Autophagy has been implicated in the pathophysiology of many neurological disorders [76,77], such as PD [12], AD [10], ALS and other neurodegenerative disorders [78,79]. The involvement of autophagy in ALS has been recently confirmed by whole-exome gene sequencing of a large cohort of ALS patients and controls [2]. The activation of autophagy is also involved in several brain injury associated disorders. Previous studies [80-82] have been implicated in ICH-induced brain injury. Thrombin, a serine protease, is produced immediately after ICH to induce hemostasis.

...
Researchers find that ICH-induced autophagic activation is associated with thrombin. Inhibition of autophagy aggravates thrombin-induced cell death after ICH [87]. Lysosome is an essential organelle for execution of autophagy activity. Lysosomal enzymes are required for degradation of the contents in autophagic vacuoles [94]. As a hydrolytic enzyme in lysosomes, cathepsin D acts as an autophagic mediator and the inhibition of cathepsin D prevents the formation of autophagic vacuoles [95]. Following ICH, cathepsin D is induced in neurons and astrocytes within 1 day, reaches peak levels after 1 week, and remains up-regulated for at least 4 weeks [84], suggesting elevated lysosomal activity and enhanced autophagy activation after ICH. In summary, multiple layers of evidence have linked autophagy and ICH-associated events (Figure 3), highlighting the crucial role autophagy in ICH pathology.

Following primary brain injuries, secondary injuries often occur through many parallel pathological pathways, such as the cytotoxicity of blood, hypermetabolism, and excitotoxicity. Meanwhile, the disturbances in cell homeostasis and the accumulations of misfolded/unfolded proteins gradually prolong ER stress, leading to sustained ER dysfunction and autophagy (Figure 2 and Figure 3). Iron is an important promoter of ICH-induced autophagic cell death and also contributes to ICH-induced brain injury [96]. As a component from plasma and hemoglobin after erythrocyte lysis, the overloaded free iron can cause free radical formation and brain damage [69]. JNK pathway activation may influence cell survival via transcriptional and post-translational regulation of proteins [97]. The fusion of iron triggers JNK pathway activation, and conversely the application of iron chelates reduce free iron levels and attenuates activation of JNK [98]. With the accumulation of free iron, ER stress is triggered, and autophagosome formation is also increased via IRE1-JNK signaling pathway [66]. These results indicate that JNK pathway is involved in iron triggered ER stress and autophagy activation. Glutamate-induced neuron toxicity is an ideal model for studying neurological diseases. The increased glutamate level in perihematomaal is a major metabolic effect of hemorrhage [99,100]. The stimulated glutamate signaling contributes to neuronal excitation and increases intracellular concentrations of calcium and sodium ions, leading to the hyper-perfusion and hyper-metabolism after ICH. The activity of autophagy can be enhanced during the process of glutamate-induced neurotoxicity, and excessive glutamate further results in ER dysfunction and initiates ER stress [101]. The disruption of Ca\(^{2+}\) homeostasis also plays an important role in neuronal function and survival after ICH [102]. ER is the major storage for cellular Ca\(^{2+}\), energy failure after ICH releases intracellular Ca\(^{2+}\) and disrupts ER-associated Ca\(^{2+}\) channels, leading to Ca\(^{2+}\) loss in ER and ER-associated Ca\(^{2+}\)-ATPase activation. Meanwhile, the failure of ERO1\(\alpha\) (ER oxidoreductin-1 alpha) disrupts protein disulfide bond formation and decreases protein folding, resulting in accumulation of unfolded proteins and activation of the UPR under ER stress [94]. COL4 (collagen, type IV) A1 and COL4A2 are the most abundant type IV collagens that are basement membrane proteins [103]. It is recently reported that COL4A1 and its mutations are associated with cerebrovascular disease pathology, including ICH [13,14]. The COL4A2 mutations that perturb collagen biosynthesis can increase the risk of sporadic ICH in humans [104]. Additionally, Mutations on COL4A1 and COL4A2 often lead to their intracellular accumulation, enhancing their cytotoxic effects. A recent study identified a dominant COL4A mutation in the collagen domain of COL4A2 which caused ER stress and UPR activation in primary fibroblasts from a hemorrhagic stroke patient, and COL4A4 mutant was shown to be degraded via the proteasome[105]. The COL4A1 and COL4A2 mutation-associated cellular pathophysiology continually triggers ER stress and the UPR, leading to irreversible cell death. These results indicate the potential role of COL4A mutation in ER stress and ICH pathology.

Numerous hypotheses have been proposed regarding the role of autophagy in other diseases. The results of studies employing autophagy inducers, autophagy inhibitors, and ATG7 knockout mice indicated that autophagy may play a role in metabolic diseases, such as obesity and diabetes, and even in the neuroendocrine system [106-109]. Autophagy is also involved in both innate and adaptive immunity, which is attributable to autophagy protein-dependent or -independent functions [110]. With regard to innate immune signaling molecules, the upregulation of autophagy enhanced immune signaling, as well as pathogen degradation and antigen presentation [111]; however, in the adaptive immune response, autophagy primarily affected the regulation of the inflammatory transcriptional response, in addition to negatively regulating inflammasome activation [112]. The role of autophagy in cancer has been well studied [113,114], but the effect of autophagy on cancer is largely unknown. While most evidences support a role of autophagy in sustaining cell survival, cell death resulting from progressive cellular consumption has been attributed to unrestrained autophagy [114]. The loss of the pro-survival function of autophagy promotes tumorigenesis. For instance, ATG5 is required for maintaining T-cell survival and proliferation. Mice with the ATG5 deletion and liver-specific ATG7 knockout were prone to develop liver adenomas, and this predisposition was attenuated by the deletion of p62 (an autophagy adaptor protein) [115]. Autophagy is also required for the survival of tumor cells to metabolic stress. In cancer cells, metabolic stress robustly induces autophagy, which is sustained when apoptosis is blocked. It is reported that autophagy may function in tumor suppression by mitigating metabolic stress. In concert with apoptosis, autophagy can also suppress tumor by preventing necrosis-induced cell death [116]. Meanwhile, in some preclinical studies, inhibition of pro-survival autophagy was shown to kill tumor cells and trigger apoptosis [116-118]. Several oncosuppressor proteins and oncoproteins, such as PTEN (phosphatase and tensin homolog), TSC1 (tuberous sclerosis 1), and RAS (a family of proteins involved in cellular signal transduction), have also been reported to stimulate or obstruct autophagy flow through mTORC1 restraint or ULK1 activation [119,120]. These results highlight the complex interactions between autophagy and cancer.
Autophagy-associated potential therapy strategies in ICH

Investigation of the autophagy mechanism is crucial for understanding the development of disease and exploring therapeutic strategies. Some reported autophagy-targeting approaches highlight the potential of autophagy modulation as a therapeutic strategy. For medical purposes, several categories of inducers and inhibitors of autophagy have been identified [121], characterized by their functional pathways, such as mTOR complex 1 targeting AMPK activity, the phosphatidylinositol signaling pathway, the cyclic AMP–associated pathway, and unforeseen autophagy-blocking effects. Other reasons for considering autophagy modulation as a possible treatment are its influence on the immune response [122,123] and its association with apoptosis and necroptosis [124,125].

Strategies to modulate the autophagy mechanism for disease treatment have been widely evaluated [113,126,127]. For now, whether inducing autophagy and ER stress after brain injury or inhibiting these processes protects neurons is still under debating. However, several encouraging progressions have been made in targeting autophagy in ICH. A rat model study [128] proved that autophagy activation induced by ischemic preconditioning may ameliorate brain damage by constraining excessive ER stress, whereas inhibiting autophagy with the inhibitor 3-MA (3-methyladenine) may result in excessive ER stress and the aggravation of ischemic neuronal damage. The results of another study in a rat middle cerebral artery occlusion (MCAO) model [129] suggested that ganglioside (GM1) inhibited autophagy and protected neurons after an experimentally induced stroke. However, this biological function could be abolished by Tat–Beclin 1, a recently identified autophagy-inducing agent [130]. Researchers investigating ICH [131,132] have proposed that autophagy contributes to microglial activation and that the inhibition of autophagy partly reduces brain damage after ICH. The effect of age was also evaluated in a rat model of ICH [86], with more severe autophagy and neurologic deficits being seen in aged rats after ICH than in younger animals.

A sex-specific study [3] in a rat model of ICH demonstrated that the suppression of ferrous citrate–induced autophagy contributes to the less severe brain injury caused by iron overload in female rats as compared to that in male rats. It was recently demonstrated in rat models that many secondary injuries caused by ICH could be substantially reduced by injecting the animals with minocycline and that the medicinal effect of minocycline was exerted through both anti-autophagy and anti-apoptosis pathways [133]. Clonidine and rilmenidine have also been reported to be pharmacologically protective against neurologic disease through their positive effect on autophagy induction [134]. Although there is still controversy as to whether the mechanisms of autophagy, ER stress, and the UPR are beneficial or detrimental to injured neurons after ICH, the above results highlight the applications and therapeutic potential of autophagy pathway modulators for the treatment of ICH.

Conclusions

For many years, there has been increasing interest in the function of autophagy in neurodegenerative disease [77,135] and cerebral ischemic injury [128,136,137]; however, ICH, despite having similar pathology and a more severe outcome, has attracted less attention. A comprehensive understanding of the roles played by autophagy in ICH and the appropriate implementation of autophagy in ICH therapy are essential. Nevertheless, there remain several challenges to exploring therapeutic applications of autophagy. For instance, although there is confidence in the potential benefits of therapeutic applications of autophagy in light of recent studies, further investigations are needed to determine whether autophagy upregulation or downregulation is the best approach, as well as to determine the appropriate time for such an intervention. Meanwhile, a better understanding of the autophagy mechanism in ICH pathophysiology and a means of determining which of the competing hypotheses is correct are both desirable. The integration of multi-omics studies, such as proteomics, genomics, and epigenetics, is also highly recommended. Furthermore, there are well-developed large-scale analysis methods and technologies that could be applied to the treatment-targeting study [129,136,138-141]. Finally, the prominent roles of autophagy and the ER stress–associated UPR in cell survival, as revealed in recent studies, have highlighted a new prospect for researchers investigating potential ICH therapies.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (grant no. 81473764 to Wei Zou) and the China Scholarship Council (certification no. 201408230060 to Mingming Niu). The authors thank Keith A. Laycock, PhD, ELS, for scientific editing of the manuscript.

Conflict of interest statement

The authors declare that they have no conflict of interest.
References

[1] Yorimitsu T., Klionsky D. J., Autophagy: molecular machinery for self-eating, Cell Death Differ., 2005, 12, 1542-1552
[2] Cirulli E. T., Lasseigne B. N., Petrovski S., Sapp P. C., Dion P. A., Leblond C. S., et al., Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways, Science (New York, N.Y.), 2015, 347, 1436-1441
[3] Chen C. W., Chen T. Y., Tsai K. L., Lin C. L., Yokoyama K. K., Lee W. S., et al., Inhibition of autophagy as a therapeutic strategy of iron-induced brain injury after hemorrhage, Autophagy, 2012, 8, 1510-1520
[4] Hetz C., The unfolded protein response: controlling cell fate decisions under ER stress and beyond, Nat. Rev. Mol. Cell Biol., 2012, 13, 89-102
[5] Rutkowski D. T., Hegde R. S., Regulation of basal cellular physiology by the homeostatic unfolded protein response, J. Cell Biol., 2010, 189, 783-794
[6] Senft D., Ronai Z. A., UPR, autophagy, and mitochondria crosstalk underlies the ER stress response, Trends Biochem. Sci., 2015, 40, 141-148
[7] Hollien J., Weissman J. S., Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response, Science (New York, N.Y.), 2006, 313, 104-107
[8] Lin J. H., Li H., Yasumura D., Cohen H. R., Zhang C., Panning B., et al., IRE1 signaling affects cell fate during the unfolded protein response, Science (New York, N.Y.), 2007, 318, 944-949
[9] Aragon T., van Anken E., Pincus D., Serafimova I. M., Korenykh A. V., Rubio C. A., et al., Messenger RNA targeting to endoplasmic reticulum stress signalling sites, Nature, 2009, 457, 736-740
[10] Salminen A., Kaarniranta K., Kauppinen A., Ojala J., Haapasalo A., Soininen H., et al., Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1 interactome, Prog. Neurobiol., 2013, 106-107, 33-54
[11] Nijholt D. A., de Graaf T. R., van Haastert E. S., Oliveira A. O., Berkers C. R., Zwart R., et al., Role of AMPK-mTOR feedbacks, Mol. Cell Biol., 2012, 32, 2-11
[12] Gan Or Z., Dion P. A., Rouleau G. A., Genetic perspective on the role of the Autophagy-Lysosome Pathway in Parkinson disease, Autophagy, 2015, 0
[13] Gould D. B., Phalan F. C., Breedveld G. J., van Mil S. E., Smith R. S., Schimenti J. C., et al., Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly, Science (New York, N.Y.), 2005, 308, 1167-1171
[14] Vahedi K., Kubis N., Boukobza M., Arnould M., Massin P., Tournier-Lasserve E., et al., COL4A1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage, Stroke; a journal of cerebral circulation, 2007, 38, 1461-1464
[15] Feigin V. L., Lawes C. M., Bennett D. A., Barker-Collo S. L., Parag V., Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review, Lancet Neurol., 2009, 8, 355-369
[16] Van Asch C. J., Luitse M. J., Rinkel G. J., van der Tweel I., Algra A., Klijn C. J., Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis, Lancet Neurol., 2010, 9, 167-176
[17] Keep R. F., Hua Y., Xi G., Intracerebral haemorrhage: mechanisms of injury and therapeutic targets, Lancet Neurol., 2012, 11, 720-731
[18] Feng Y., He D., Yao Z., Klionsky D. J., The machinery of macroautophagy, Cell Res., 2014, 24, 24-41
[19] Stricher F., Macri C., Ruff M., Muller S., HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting, Autophagy, 2013, 9, 1937-1954
[20] Kaufshik S., Cuervo A. M., Chaperone-mediated autophagy: a unique way to enter the lysosome world, Trends Cell Biol., 2012, 22, 407-417
[21] Mehta P., Renault J., Kolbeck R., Sanjuan M. A., Noncanonical autophagy: one small step for LC3, one giant leap for immunity, Curr. Opin. Immunol., 2014, 26, 69-75
[22] Mizushima N., Yoshimori T., Ohsumi Y., The role of Atg proteins in autophagosome formation, Annu. Rev. Cell Dev. Biol., 2011, 27, 107-132
[23] Furuya Y., Yu J., Byfield M., Pattingre S., Levine B., The Evolutionarily Conserved Domain of Beclin 1 is Required for Vps34 Binding, Autophagy, and Tumor Suppressing Function, Autophagy, 2005, 1, 46-52
[24] Tanida I., Minematsu-Ikeguchi N., Ueno T., Kominami E., Lysosomal Turnover, but Not a Cellular Level, of Endogenous LC3 is a Marker for Autophagy, Autophagy, 2005, 1, 84-91
[25] Wong P.-M., Puente C., Ganley I. G., Jiang X., The ULK1 complex, Autophagy, 2013, 9, 124-137
[26] Laplante M., Sabatini D. M., mTOR signaling in growth control and disease, Cell, 2012, 149, 274-293
[27] Kim J., Kundu M., Violet B., Guan K.-L., AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1, Nat. Cell Biol., 2011, 13, 132-141
[28] Alers S., Loffler A. S., Wesselborg S., Stork B., Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks, Mol. Cell Biol., 2012, 32, 2-11
[29] Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., Bordi M., et al., mTOR inhibits autophagy by controlling ULK1 ubiquitination, self-association and function through AMBRA1 and TRAF6, Nat. Cell Biol., 2013, 15, 406-416
[30] Strappazzon F., Vietri-Rudan M., Campello S., Nazio F., Florenzano F., Fimia G. M., et al., Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy, EMBO J., 2011, 30, 1195-1208
[31] Ragusa M. J., Stanley R. E., Hurley J. H., Architecture of the Atg17 complex as a scaffold for autophagosome biogenesis, Cell, 2013, 151, 1501-1512
[32] Lu Q., Yang P., Huang X., Hu W., Guo B., Wu F., et al., The WD40 repeat PtdIns(3)P-binding protein EPG-6 regulates progression of...
omegasomes to autophagosomes, Dev. Cell., 2011, 21, 343-357

[33] Vergne I., Roberts E., Elmaoued R. A., Tosch V., Delgado M. A., Prokai-Cezanne T., et al., Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy, EMBO J., 2009, 28, 2244-2258

[34] Klionsky D. J., The molecular machinery of autophagy: unanswered questions, J. Cell Sci., 2005, 118, 7-18

[35] Orsi A., Razi M., Dooley H. C., Robinson D., Weston A. E., Collinson L. M., et al., Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy, Mol. Biol. Cell, 2012, 23, 1860-1873

[36] Zhou C., Ma K., Gao R., Mu C., Chen L., Liu Q., et al., Regulation of mATG9 trafficking by Src- and ULK1-mediated phosphorylation in basal and starvation-induced autophagy, Cell Res., 2017, 27, 184-201

[37] Lamb C. A., Yoshimori T., Tooze S. A., The autophagosome: origins unknown, biogenesis complex, Nat. Rev. Mol. Cell Biol., 2013, 14, 759-774

[38] Kozutsumi Y., Segal M., Normington K., Gething M. J., Sambrook J., Clark K., et al., Identification of the G13 (cAMP-response-element-binding protein-related protein) gene product related to activating transcription factor 6 as a transcriptional activator of the mammalian unfolded protein response, Biochem. J., 2001, 355, 19-28

[39] Thuerauf D. J., Marcinko M., Belmont P. J., Glembocki C. L., Effects of the isoform-specific characteristics of ATF6 alpha and ATF6 beta on endoplasmic reticulum stress response gene expression and cell viability, J. Biol. Chem., 2007, 282, 22865-22878

[40] Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., et al., ER stress negatively regulates AKT/mTOR signaling through the transcriptional induction of mammalian ER quality control proteins, Mol. Cell, 2010, 22, 124-131

[41] Qin L., Wang Z., Tao L., Wang Y., ER stress negatively regulates AKT/mTOR signaling, Mol. Cell, 2014, 54, 166-179

[42] Houck S. A., Ren H. Y., Madden V. J., Bonner J. N., Conlin M. P., Janovick J. A., et al., Quality control autophagy degrades soluble ERAD-resistant conformers of the misfolded membrane protein GnRHR, J. Proteins, 2014, 8, 519-529

[43] Shen J., Snapp E. L., Lippincott-Schwartz J., Prywes R., Dynamic interaction of BIP and ER stress transducers in the unfolded-protein response, Cell, 1996, 87, 391-404

[44] Cox J. S., Walter P., A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response, Cell, 1996, 87, 357-359

[45] Kozutsumi Y., Segal M., Normington K., Gething M. J., Sambrook J., Clark K., et al., Identification of the G13 (cAMP-response-element-binding protein-related protein) gene product related to activating transcription factor 6 as a transcriptional activator of the mammalian unfolded protein response, Biochem. J., 2001, 355, 19-28

[46] Thuerauf D. J., Marcinko M., Belmont P. J., Glembocki C. L., Effects of the isoform-specific characteristics of ATF6 alpha and ATF6 beta on endoplasmic reticulum stress response gene expression and cell viability, J. Biol. Chem., 2007, 282, 22865-22878

[47] Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., et al., ER stress negatively regulates AKT/mTOR signaling through the transcriptional induction of mammalian ER quality control proteins, Mol. Cell, 2010, 22, 124-131
al., Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy, Mol. Biol. Cell, 2009, 20, 1981-1991

[64] B’Chir W., Maurin A. C., Carraro V., Averous J., Jousse C., Munanishi Y., et al., The elf2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression, Nucleic Acids Res., 2013, 41, 7683-7699

[65] Adolph T. E., Tomczak M. F., Niedeerleiter L., Ko H. J., Bock J., Martinez-Naves E., et al., Paneth cells as a site of origin for intestinal inflammation, Nature, 2013, 503, 272-276

[66] Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., et al., Autophagy is activated for cell survival after endoplasmic reticulum stress, Mol. Cell Biol., 2006, 26, 9220-9231

[67] Deegan S., Saveljeva S., Gorman A. M., Samali A., Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress, Cell Mol. Life Sci., 2013, 70, 2425-2441

[68] Rashid H. O., Yadav R. K., Kim H. R., Chae H. J., ER stress: Autophagy induction, inhibition and selection, Autophagy, 2015, 11, 1956-1977

[69] Xi G., Keep R. F., Hoff J. T., Mechanisms of brain injury after intracerebral haemorrhage, Lancet Neurol., 2006, 5, S3-63

[70] Morgenstern L. B., Hemphill J. C., Anderson C., Becker K., Broderick J. P., Connolly E. S., Jr., et al., Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke: a journal of cerebral circulation, 2010, 41, 2108-2129

[71] Liu J., Gao B. B., Clermont A. C., Blair P., Chilcote T. J., Sinha S., et al., Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kalikrein, Nat. Med., 2011, 17, 206-210

[72] Herweh C., Juttler E., Schellinger P. D., Klotz E., Jenetzky E., Orakcioglu B., et al., Evidence against a perihemorrhagic penumbra provided by perfusion computed tomography, Stroke; a journal of cerebral circulation, 2007, 38, 2941-2947

[73] Urday S., Beslow L. A., Goldstein D. W., Vashkevich A., Ayres A. M., Battey T. W., et al., Measurement of perihematomal edema in intracerebral hemorrhage, Stroke; a journal of cerebral circulation, 2015, 46, 1116-1119

[74] Aronowski J., Zhao X., Molecular pathophysiology of cerebral hemorrhage: secondary brain injury, Stroke; a journal of cerebral circulation, 2011, 42, 1781-1786

[75] Guo F., Hua Y., Wang J., Keep R. F., Xi G., Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage, Transl. Stroke Res., 2012, 3, 130-137

[76] Mizushima N., Levine B., Cuervo A. M., Klionsky D. J., Autophagy fights disease through cellular self-digestion, Nature, 2008, 451, 1069-1075

[77] Nixon R. A., The role of autophagy in neurodegenerative disease, Nat. Med., 2013, 19, 983-997

[78] Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al., Loss of autophagy in the central nervous system causes neurodegeneration in mice, Nature, 2006, 441, 880-884

[79] Hara T., Nakamura K., Matsu M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al., Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice, Nature, 2006, 441, 885-889

[80] Liu C., Gao Y., Barrett J., Hu B., Autophagy and protein aggregation after brain ischemia, J. Neurochem., 2010, 115, 68-78

[81] Adhami F., Schloemer A., Kuan C. Y., The roles of autophagy in cerebral ischemia, Autophagy, 2007, 3, 42-44

[82] Zuo C., Yang X., Fu F., Bahr B. A., Shibata M., Uchiyama Y., et al., The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia, Cell Death Differ., 2005, 12, 162-176

[83] Sarkar C., Zhao Z., Aungst S., Sabirzhanov B., Faden A. I., Lipinski M. M., Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury, Autophagy, 2014, 10, 2208-2222

[84] He Y., Han S., Hua Y., Keep R. F., Xi G., Autophagy after experimental intracerebral hemorrhage, J. Cereb. Blood Flow Metab., 2008, 28, 897-905

[85] Wang Z., Shi X.-Y., Yin J., Zuo G., Zhang J., Chen G., Role of Autophagy in Early Brain Injury after Experimental Subarachnoid Hemorrhage, J. Mol. Neurosci., 2012, 46, 192-202

[86] Gong Y., He Y., Gu Y., Keep R. F., Xi G., Hua Y., Effects of aging on autophagy after experimental intracerebral hemorrhage, Acta Neurochir. Suppl., 2011, 111, 113-117

[87] Hu S., Xi G., Jin H., He Y., Keep R. F., Hua Y., Thrombin-induced autophagy: A potential role in intracerebral hemorrhage, Brain Research, 2011, 1424, 60-66

[88] Hwang B. Y., Appelboom G., Ayer A., Kellner C. P., Kotchetkov I. S., Gigante P. R., et al., Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage, Cerebrovasc. Dis., 2011, 31, 211-222

[89] Wang J., Dore S., Inflammation after intracerebral hemorrhage, J. Cereb. Blood Flow Metab., 2007, 27, 894-908

[90] Yang Z., Zhao T.-z., Zou Y.-j., Zhang J. H., Feng H., Hypoxia Induces Autophagic Cell Death through Hypoxia-Inducible Factor 1α in Microglia, PLoS ONE, 2014, 9, e96509

[91] Yu A., Zhang T., Zhong W., Duan H., Wang S., Ye P., et al., miRNA-144 induces microglial autophagy and inflammation following intracerebral hemorrhage, Immunol. Lett., 2017, 182, 18-23

[92] Remijsen Q., Berghe T. V., Wirawan E., Asselbergh B., Parthoens E., Defilippi D. R., et al., Neutrophil extracellular trap cell death requires both autophagy and superoxide generation, Cell Res., 2011, 21, 290-304

[93] Moxon-Emre I., Schlichter L. C., Neutrophil Depletion Reduces Blood-Brain Barrier Breakdown, Axon Injury, and Inflammation After Intracerebral Hemorrhage, J. Neuropathol. Exp. Neurol., 2011, 70, 218-235

[94] Wen Y.-D., Sheng R., Zhang L.-S., Han R., Zhang X., Zhang X.-D., et al., Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways, Autophagy, 2008, 4, 762-769

[95] Araki T., Hayashi M., Saruta T., Anion-exchange blocker enhances cyttoplasmic vacuole formation and cell death in serum-deprived mouse kidney epithelial cells in mice, Cell Biol. Int., 2006, 30, 93-100
[96] Hua Y., Keep R. F., Hoff J. T., Xi G., Brain injury after intracerebral hemorrhage: the role of thrombin and iron, Stroke; a journal of cerebral circulation, 2007, 38, 759-762

[97] Manning A. M., Davis R. J., Targeting JNK for therapeutic benefit: from junk to gold?, Nat. Rev. Drug Discov., 2003, 2, 554-565

[98] Wan S., Zhan R., Zheng S., Hua Y., Xi G., Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron, Neurosci. Res., 2009, 63, 100-105

[99] Sharp F., Liu D.-Z., Zhan X., Ander B. P., In Cerebral Hemorrhage, Springer Vienna, Vienna, 2008

[100] Wagner K. R., Modeling intracerebral hemorrhage: glutamate, nuclear factor-kappa B signaling and cytokines, Stroke; a journal of cerebral circulation, 2007, 38, 753-758

[101] Chen Z., Lu T., Yue X., Wei N., Jiang Y., Chen M., et al., Neuroprotective effect of ginsenoside Rb1 on glutamate-induced neurotoxicity: With emphasis on autophagy, Neurosci. Lett., 2010, 482, 264-268

[102] Xu C., Bailly-Maitre B., Reed J. C., Endoplasmic reticulum stress: cell life and death decisions, J. Clin. Invest., 2005, 115, 2656-2664

[103] Urabe N., Naito I., Saito K., Yonezawa T., Sado Y., Yoshiooka H., et al., Basement membrane type IV collagen molecules in the choroid plexus, pia mater and capillaries in the mouse brain, Arch. Histol. Cytol, 2002, 65, 133-143

[104] Jeanne M., Labelle-Dumais C., Jorgensen J., Kauffman W. B., Mancini G. M., Favor J., et al., COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke, Am. J. Hum. Genet., 2012, 90, 91-101

[105] Murray L. S., Lu Y., Taggart A., Van Regemorter N., Vilain C., Abramowicz M., et al., Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke, Hum. Mol. Genet., 2014, 23, 283-292

[106] Yang L., Li P., Fu S., Calay E. S., Hotamisligil G. S., Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance, Cell Metab., 2010, 11, 467-478

[107] Codogno P., Meijer A. J., Autophagy: a potential link between obesity and insulin resistance, Cell Metab., 2010, 11, 449-451

[108] Kaushik S., Rodriguez-Navarro J. A., Arias E., Kiffin R., Sahu S., Schwartz G. J., et al., Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance, Cell Metab., 2011, 14, 173-183

[109] He C., Bassik M. C., Moresi V., Sun K., Wei Y., Zou Z., et al., Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis, Nature, 2012, 481, 511-515

[110] Levine B., Mizushima N., Virgin H. W., Autophagy in immunity and inflammation, Nature, 2011, 469, 323-335

[111] Meissner F., Molawi K., Zychlinsky A., Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 13046-13050

[112] Saitoh T., Fujita N., Jang M. H., Uematsu S., Yang B. G., Satoh T., et al., Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production, Nature, 2008, 456, 264-268

[113] Yang Z. J., Chee C. E., Huang S., Sinicrope F. A., The role of autophagy in cancer: therapeutic implications, Mol. Cancer Ther., 2011, 10, 1533-1541

[114] Mathew R., Karantza-Wadsworth V., White E., Role of autophagy in cancer, Nat. Rev. Cancer, 2007, 7, 961-967

[115] Takamura A., Komatsu M., Hara T., Sakamoto A., Kishi C., Waguri S., et al., Autophagy-deficient mice develop multiple liver tumors, Genes Dev., 2011, 25, 795-800

[116] Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al., Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis, Cancer cell, 2006, 10, 51-64

[117] White E., DiPaola R. S., The double-edged sword of autophagy modulation in cancer, Clin. Cancer Res., 2009, 15, 5308-5316

[118] Ding W. X., Ni H. M., Gao W., Chen X., Kang J. H., Stolz D. B., et al., Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy, Mol. Cancer Ther., 2009, 8, 2036-2045

[119] Morselli E., Galluzzi L., Kepp O., Marino G., Michaud M., Vitale I., et al., Oncosuppressive functions of autophagy, Antioxid. Redox Signal., 2011, 14, 2251-2269

[120] Yin D., Xia X., Zhang J., Zhang S., Liao F., Zhang G., et al., Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose, Oncotarget, 2017

[121] Rubinsztein D. C., Codogno P., Levine B., Autophagy modulation as a potential therapeutic target for diverse diseases, Nat. Rev. Drug Discov., 2012, 11, 709-730

[122] Michaud M., Martins I., Sukkurwala A. Q., Adjemian S., Ma Y., Pellegratti P., et al., Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science (New York, N.Y.), 2011, 334, 1573-1577

[123] Rao S., Tortola L., Perlot T., Wünscherger G., Novatchokova M., Nitsch R., et al., A dual role for autophagy in a murine model of lung cancer, Nat. Commun., 2014, 5, 3056

[124] Jin S. M., Jang H. W., Sohn S. Y., Kim N. K., Joung J. Y., Cho Y. Y., et al., Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells, Endocrine, 2014, 45, 256-262

[125] Marino G., Niso-Santano M., Baehrecke E. H., Kroemer G., Self-consumption: the interplay of autophagy and apoptosis, Nat. Rev. Mol. Cell Biol., 2014, 15, 81-94

[126] Janku F., McConkey D. J., Hong D. S., Kurzrock R., Autophagy as a target for anticancer therapy, Nat. Rev. Clin. Oncol., 2011, 8, 528-539

[127] Pal I., Parida S., Prashanth Kumar B. N., Banik P., Kumar Dey K., Chakraborty S., et al., Blockade of autophagy enhances proapoptotic potential of BI-69A11, a novel Akt inhibitor, in colon carcinoma, Eur. J. Pharmacol., 2015, 765, 217-227

[128] Sheng R., Liu X. Q., Zhang L. S., Gao B., Han R., Wu Y. Q., et al., Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning, Autophagy, 2012, 8, 310-325
[129] Li L., Tian J., Long M. K.-W., Chen Y., Lu J., Zhou C., et al., Protection against Experimental Stroke by Ganglioside GM1 Is Associated with the Inhibition of Autophagy, PLoS ONE, 2016, 11, e0144219

[130] Shoji-Kawata S., Sumpter R., Leveno M., Campbell G. R., Zou Z., Kinch L., et al., Identification of a candidate therapeutic autophagy-inducing peptide, Nature, 2013, 494, 201-206

[131] Yuan B., Shen H., Lin L., Su T., Zhong L., Yang Z., Autophagy Promotes Microglia Activation Through Beclin-1-Atg5 Pathway in Intracerebral Hemorrhage, Mol. Neurobiol., 2016, 1-10

[132] Yang Z., Liu B., Zhong L., Shen H., Lin C., Lin L., et al., Toll-like receptor-4-mediated autophagy contributes to microglial activation and inflammatory injury in mouse models of intracerebral haemorrhage, Neuropath. Appl. Neuro., 2015, 41, e95-e106

[133] Wu Z., Zou X., Zhu W., Mao Y., Chen L., Zhao F., Minocycline is effective in intracerebral hemorrhage by inhibition of apoptosis and autophagy, J. Neurol. Sci., 2016, 371, 88-95

[134] Rose C., Menzies F. M., Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., et al., Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease, Hum. Mol. Genet., 2010, 19, 2144-2153

[135] Rubinstein D. C., Marino G., Kroemer G., Autophagy and aging, Cell, 2011, 146, 682-695

[136] Wang P., Xu T.-Y., Wei K., Guan Y.-F., Wang X., Xu H., et al., ARRB1/β-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia, Autophagy, 2014, 10, 1535-1548

[137] Zhang X., Yuan Y., Jiang L., Zhang J., Gao J., Shen Z., et al., Endoplasmic reticulum stress induced by tunicamycin and thapsigargin protects against transient ischemic brain injury: Involvement of PARK2-dependent mitophagy, Autophagy, 2014, 10, 1801-1813

[138] Tan H., Wu Z., Wang H., Bai B., Li Y., Wang X., et al., Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome, Proteomics, 2014, 15, 500-507

[139] Wang H., Yang Y., Li Y., Bai B., Wang X., Tan H., et al., Systematic optimization of long gradient chromatography mass spectrometry for deep analysis of brain proteome, J. Proteome Res., 2015, 14, 829-838

[140] Wang X., Li Y., Wu Z., Wang H., Tan H., Peng J., JUMP: A Tag-based Database Search Tool for Peptide Identification with High Sensitivity and Accuracy, Mol. Cell Proteomics, 2014, 13, 3663-3673

[141] Li Y., Wang X., Cho J. H., Shaw T. I., Wu Z., Bai B., et al., JUMPg: An Integrative Proteogenomics Pipeline Identifying Unannotated Proteins in Human Brain and Cancer Cells, J. Proteome Res., 2016, 15, 2309-2320